LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 188

Search options

  1. Book ; Conference proceedings: The challenge of drug induced liver injury (DILI)

    Gerbes, Alexander L.

    Falk Workshop, Freiburg, October 9, 2014 ; Challenges and management of liver cirrhosis ; Falk Symposium 195, Freiburg, October 10 - 11, 2014 ; official congress report ; 22 tables

    (Digestive diseases ; 33,4)

    2015  

    Title variant The challenge of drug-induced liver injury (DILI)
    Event/congress Falk Workshop (2014, FreiburgimBreisgau) ; Falk Symposium (195., 2014, FreiburgimBreisgau)
    Author's details ed. A. L. Gerbes
    Series title Digestive diseases ; 33,4
    Collection
    Keywords Gastroenterology ; Hepatose ; Arzneimittelschaden ; Leberzirrhose
    Subject Cirrhosis hepatis ; Hepatitis interstitialis chronica ; Hepatocirrhus ; Lebercirrhose ; Leberschrumpfung ; Arzneimittel ; Leberschaden
    Language English
    Size S. 457 - 627 : Ill., graph. Darst.
    Publisher Karger
    Publishing place Basel u.a.
    Publishing country Switzerland
    Document type Book ; Conference proceedings
    HBZ-ID HT018698515
    ISBN 978-3-318-05446-0 ; 3-318-05446-1 ; 9783318054477 ; 331805447X
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  2. Article ; Online: Drug-Induced Liver Injury (DILI): A Major Challenge.

    Gerbes, Alexander L

    Drug research

    2021  Volume 71, Issue S 01, Page(s) S7

    MeSH term(s) Chemical and Drug Induced Liver Injury/etiology ; Humans ; Liver
    Language English
    Publishing date 2021-11-17
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 2703847-6
    ISSN 2194-9387 ; 2194-9379
    ISSN (online) 2194-9387
    ISSN 2194-9379
    DOI 10.1055/a-1606-5411
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Update on herbal and dietary supplement-induced liver injury: current gaps and future directions.

    Weber, Sabine / Gerbes, Alexander L

    Hepatobiliary surgery and nutrition

    2023  Volume 12, Issue 5, Page(s) 752–755

    Language English
    Publishing date 2023-09-01
    Publishing country China (Republic : 1949- )
    Document type Editorial ; Comment
    ZDB-ID 2812398-0
    ISSN 2304-389X ; 2304-3881
    ISSN (online) 2304-389X
    ISSN 2304-3881
    DOI 10.21037/hbsn-23-329
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Book: Ascites, hyponatremia and hepatorenal syndrome: progress in treatment

    Gerbes, Alexander L.

    31 tables

    (Frontiers of gastrointestinal research ; 28)

    2011  

    Author's details Vol. ed. Alexander L. Gerbes
    Series title Frontiers of gastrointestinal research ; 28
    Collection
    Keywords Liver Cirrhosis / complications ; Liver Cirrhosis / therapy ; Ascites / therapy ; Hyponatremia / therapy ; Hepatorenal Syndrome / therapy ; Hepatorenales Syndrom ; Ascites ; Therapie
    Subject Medizinische Behandlung ; Behandlung ; Krankenbehandlung ; Aszites ; Bauchwassersucht
    Language English
    Size VIII, 212 S. : graf. Darst.
    Publisher Karger
    Publishing place Basel u.a.
    Publishing country Switzerland
    Document type Book
    HBZ-ID HT016656612
    ISBN 978-3-8055-9591-9 ; 9783805595926 ; 3-8055-9591-3 ; 3805595921
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  5. Article ; Online: Relapse and Need for Extended Immunosuppression: Novel Features of Drug-Induced Autoimmune Hepatitis.

    Weber, Sabine / Gerbes, Alexander L

    Digestion

    2023  Volume 104, Issue 3, Page(s) 243–248

    Abstract: Background: Drug-induced autoimmune hepatitis (DI-AIH) has been proposed as a distinct phenotype of drug-induced liver injury (DILI), and frequently has been associated with specific drugs, such as minocycline and nitrofurantoin. However, no clear ... ...

    Abstract Background: Drug-induced autoimmune hepatitis (DI-AIH) has been proposed as a distinct phenotype of drug-induced liver injury (DILI), and frequently has been associated with specific drugs, such as minocycline and nitrofurantoin. However, no clear definition of DI-AIH has been established thus far.
    Objectives: We aimed to identify features distinguishing DI-AIH from DILI and idiopathic autoimmune hepatitis (AIH) in an attempt to further define a DI-AIH phenotype.
    Method: A cohort of 38 previously reported DILI and AIH patients who were prospectively recruited at our tertiary centre and who received corticosteroid was analysed regarding the phenotypical presentation and outcome of DI-AIH, DILI, and AIH.
    Results: AIH (n = 19), DILI (n = 8), and DI-AIH (n = 11) patients presented with similar clinical features at onset, with the only difference being a higher Roussel Uclaf Causality Assessment Method (RUCAM) score in the DILI and DI-AIH patients. Post-treatment AIH scores were lower and a more rapid decrease of alanine aminotransferase in the first week of corticosteroid treatment was observed in both DILI groups when compared to AIH patients, while no significant differences were observed between DI-AIH and DILI patients. Relapse occurred in DI-AIH but not in DILI patients (36% vs. 0%) with a more frequent need for long-term immunosuppression (27% vs. 13%).
    Conclusions: Our data show that relapse after cessation of corticosteroids and need for further immunosuppressive treatment does occur in a substantial proportion of DI-AIH patients. However, no other phenotypical differences between DILI due to agents commonly associated with DI-AIH and DILI due to other drugs were identified.
    MeSH term(s) Humans ; Hepatitis, Autoimmune/diagnosis ; Hepatitis, Autoimmune/drug therapy ; Hepatitis, Autoimmune/etiology ; Chemical and Drug Induced Liver Injury/diagnosis ; Chemical and Drug Induced Liver Injury/etiology ; Recurrence ; Adrenal Cortex Hormones ; Immunosuppression Therapy/adverse effects
    Chemical Substances Adrenal Cortex Hormones
    Language English
    Publishing date 2023-01-05
    Publishing country Switzerland
    Document type News
    ZDB-ID 1712-7
    ISSN 1421-9867 ; 0012-2823
    ISSN (online) 1421-9867
    ISSN 0012-2823
    DOI 10.1159/000528329
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: COVID-19 and liver injury: hypoalbuminaemia and γGT should be observed at hospital admission.

    Weber, Sabine / Gerbes, Alexander L

    Gut

    2022  Volume 72, Issue 6, Page(s) 1229–1230

    MeSH term(s) Humans ; Hypoalbuminemia ; COVID-19 ; Liver ; gamma-Glutamyltransferase ; Hospitals ; Retrospective Studies
    Chemical Substances gamma-Glutamyltransferase (EC 2.3.2.2)
    Language English
    Publishing date 2022-07-27
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 80128-8
    ISSN 1468-3288 ; 0017-5749
    ISSN (online) 1468-3288
    ISSN 0017-5749
    DOI 10.1136/gutjnl-2022-328214
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Drug-Induced Liver Injury (DILI): A Major Challenge

    Gerbes, Alexander L.

    Drug Research

    2021  Volume 71, Issue S 01, Page(s) S7–S7

    Language English
    Publishing date 2021-11-01
    Publisher Georg Thieme Verlag KG
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 2703847-6
    ISSN 2194-9387 ; 2194-9379
    ISSN (online) 2194-9387
    ISSN 2194-9379
    DOI 10.1055/a-1606-5411
    Database Thieme publisher's database

    More links

    Kategorien

  8. Article ; Online: Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers.

    Trebicka, Jonel / Hernaez, Ruben / Shawcross, Debbie Lindsay / Gerbes, Alexander L

    Gut

    2024  

    Abstract: The progression of cirrhosis with clinically significant portal hypertension towards decompensated cirrhosis remains clinically challenging and the evolution towards acute-on-chronic liver failure (ACLF), with one or more extrahepatic organ failures, is ... ...

    Abstract The progression of cirrhosis with clinically significant portal hypertension towards decompensated cirrhosis remains clinically challenging and the evolution towards acute-on-chronic liver failure (ACLF), with one or more extrahepatic organ failures, is associated with very high mortality. In the last decade, significant progress has been made in the understanding of the mechanisms leading to decompensation and ACLF. As portal hypertension advances, bacterial translocation across an impaired gut barrier culminates in endotoxaemia, systemic inflammation and cirrhosis-associated immune dysfunction (CAID). Gut-derived systemic inflammation and CAID have become the logical targets for innovative therapies that prevent hepatic decompensation episodes and the progression to ACLF.Furthermore, classification of disease and biomarker discovery to personalise care have advanced in the field. This review discusses progress in biomarker discovery and personalisation of treatment in decompensated cirrhosis and ACLF.
    Language English
    Publishing date 2024-03-25
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 80128-8
    ISSN 1468-3288 ; 0017-5749
    ISSN (online) 1468-3288
    ISSN 0017-5749
    DOI 10.1136/gutjnl-2023-330584
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Challenges and Future of Drug-Induced Liver Injury Research-Laboratory Tests.

    Weber, Sabine / Gerbes, Alexander L

    International journal of molecular sciences

    2022  Volume 23, Issue 11

    Abstract: Drug-induced liver injury (DILI) is a rare but potentially severe adverse drug event, which is also a major cause of study cessation and market withdrawal during drug development. Since no acknowledged diagnostic tests are available, DILI diagnosis poses ...

    Abstract Drug-induced liver injury (DILI) is a rare but potentially severe adverse drug event, which is also a major cause of study cessation and market withdrawal during drug development. Since no acknowledged diagnostic tests are available, DILI diagnosis poses a major challenge both in clinical practice as well as in pharmacovigilance. Differentiation from other liver diseases and the identification of the causative agent in the case of polymedication are the main issues that clinicians and drug developers face in this regard. Thus, efforts have been made to establish diagnostic testing methods and biomarkers in order to safely diagnose DILI and ensure a distinguishment from alternative liver pathologies. This review provides an overview of the diagnostic methods used in differential diagnosis, especially with regards to autoimmune hepatitis (AIH) and drug-induced autoimmune hepatitis (DI-AIH), in vitro causality methods using individual blood samples, biomarkers for diagnosis and severity prediction, as well as experimental predictive models utilized in pre-clinical settings during drug development regimes.
    MeSH term(s) Biomarkers ; Chemical and Drug Induced Liver Injury/diagnosis ; Chemical and Drug Induced Liver Injury/pathology ; Hepatitis, Autoimmune/pathology ; Humans ; Liver/pathology ; Liver Diseases/pathology
    Chemical Substances Biomarkers
    Language English
    Publishing date 2022-05-27
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms23116049
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Liver Involvement.

    Gerbes, Alexander L / Weber, Sabine

    Deutsches Arzteblatt international

    2021  Volume 117, Issue 42, Page(s) 717

    MeSH term(s) COVID-19 ; Humans ; Liver/diagnostic imaging ; Neoplasm Staging ; Respiratory Distress Syndrome ; SARS-CoV-2
    Language English
    Publishing date 2021-02-09
    Publishing country Germany
    Document type Letter ; Comment
    ZDB-ID 2406159-1
    ISSN 1866-0452 ; 1866-0452
    ISSN (online) 1866-0452
    ISSN 1866-0452
    DOI 10.3238/arztebl.2020.0717a
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top